FR2938431B1 - Nouvelle composition a base d'acide gamma-hydroxybutyrique - Google Patents

Nouvelle composition a base d'acide gamma-hydroxybutyrique

Info

Publication number
FR2938431B1
FR2938431B1 FR0857763A FR0857763A FR2938431B1 FR 2938431 B1 FR2938431 B1 FR 2938431B1 FR 0857763 A FR0857763 A FR 0857763A FR 0857763 A FR0857763 A FR 0857763A FR 2938431 B1 FR2938431 B1 FR 2938431B1
Authority
FR
France
Prior art keywords
gamma
hydroxybutyric acid
composition based
novel composition
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0857763A
Other languages
English (en)
French (fr)
Other versions
FR2938431A1 (fr
Inventor
Christophe Lebon
Pascal Suplie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debregeas Et Associes Pharma SAS
Original Assignee
Debregeas Et Associes Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40674006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2938431(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debregeas Et Associes Pharma SAS filed Critical Debregeas Et Associes Pharma SAS
Priority to FR0857763A priority Critical patent/FR2938431B1/fr
Priority to DK09768176T priority patent/DK2349217T3/da
Priority to CN2009801457609A priority patent/CN102215822A/zh
Priority to HRP20191911TT priority patent/HRP20191911T1/hr
Priority to BRPI0916021A priority patent/BRPI0916021B8/pt
Priority to LT09768176T priority patent/LT2349217T/lt
Priority to EA201100758A priority patent/EA023305B1/ru
Priority to NZ592850A priority patent/NZ592850A/xx
Priority to CN201510047649.3A priority patent/CN104688691A/zh
Priority to KR1020117013587A priority patent/KR101563390B1/ko
Priority to US13/129,130 priority patent/US8529954B2/en
Priority to PCT/FR2009/052169 priority patent/WO2010055260A1/fr
Priority to SM20190721T priority patent/SMT201900721T1/it
Priority to SI200932005T priority patent/SI2349217T1/sl
Priority to MX2011005073A priority patent/MX2011005073A/es
Priority to PT97681761T priority patent/PT2349217T/pt
Priority to PL09768176T priority patent/PL2349217T3/pl
Priority to CA2743767A priority patent/CA2743767C/fr
Priority to HUE09768176A priority patent/HUE046321T2/hu
Priority to ES09768176T priority patent/ES2749803T3/es
Priority to PE2011001031A priority patent/PE20120028A1/es
Priority to AU2009315441A priority patent/AU2009315441B2/en
Priority to EP09768176.1A priority patent/EP2349217B1/fr
Priority to UAA201105987A priority patent/UA103057C2/ru
Priority to JP2011543797A priority patent/JP2012508784A/ja
Priority to TW098138675A priority patent/TWI446906B/zh
Priority to ARP090104424A priority patent/AR074351A1/es
Publication of FR2938431A1 publication Critical patent/FR2938431A1/fr
Priority to TN2011000231A priority patent/TN2011000231A1/fr
Priority to IL212847A priority patent/IL212847A/en
Priority to CO11059012A priority patent/CO6382106A2/es
Priority to CL2011001114A priority patent/CL2011001114A1/es
Priority to CU20110109A priority patent/CU20110109A7/es
Priority to ZA2011/03542A priority patent/ZA201103542B/en
Priority to MA33838A priority patent/MA32790B1/fr
Publication of FR2938431B1 publication Critical patent/FR2938431B1/fr
Application granted granted Critical
Priority to CY20191101121T priority patent/CY1122209T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0857763A 2008-11-14 2008-11-14 Nouvelle composition a base d'acide gamma-hydroxybutyrique Expired - Fee Related FR2938431B1 (fr)

Priority Applications (35)

Application Number Priority Date Filing Date Title
FR0857763A FR2938431B1 (fr) 2008-11-14 2008-11-14 Nouvelle composition a base d'acide gamma-hydroxybutyrique
HUE09768176A HUE046321T2 (hu) 2008-11-14 2009-11-10 Gamma-hidroxivajsav granulátum
ES09768176T ES2749803T3 (es) 2008-11-14 2009-11-10 Nueva composición a base de ácido gamma-hidroxibutírico
HRP20191911TT HRP20191911T1 (hr) 2008-11-14 2009-11-10 Granule gama-hidroksibutirične kiseline
BRPI0916021A BRPI0916021B8 (pt) 2008-11-14 2009-11-10 grânulo de ácido gama-hidroxibutírico, composição farmacêutica e processo de preparação de um grânulo
LT09768176T LT2349217T (lt) 2008-11-14 2009-11-10 Gama-hidroksisviesto rūgšties granulė
EA201100758A EA023305B1 (ru) 2008-11-14 2009-11-10 Гранулят гамма-гидроксимасляной кислоты
NZ592850A NZ592850A (en) 2008-11-14 2009-11-10 Granulate of gamma-hydroxybutyric acid
CN201510047649.3A CN104688691A (zh) 2008-11-14 2009-11-10 基于γ-羟基丁酸的新型组合物
KR1020117013587A KR101563390B1 (ko) 2008-11-14 2009-11-10 감마-하이드록시부티르산을 주성분으로 하는 신규 조성물
US13/129,130 US8529954B2 (en) 2008-11-14 2009-11-10 Composition based on gamma-hydroxybutyric acid
PCT/FR2009/052169 WO2010055260A1 (fr) 2008-11-14 2009-11-10 Nouvelle composition à base d'acide gamma-hydroxybutyrique
SM20190721T SMT201900721T1 (it) 2008-11-14 2009-11-10 Granulato di acido gamma-idrossibutirrico
SI200932005T SI2349217T1 (sl) 2008-11-14 2009-11-10 Granula gama-hidroksimaslene kisline
MX2011005073A MX2011005073A (es) 2008-11-14 2009-11-10 Nueva composicion a base de acido gamma-hidroxibutirico.
PT97681761T PT2349217T (pt) 2008-11-14 2009-11-10 Granulado de ácido gama-hidroxibutírico
PL09768176T PL2349217T3 (pl) 2008-11-14 2009-11-10 Granulat kwasu gamma-hydroksymasłowego
CN2009801457609A CN102215822A (zh) 2008-11-14 2009-11-10 基于γ-羟基丁酸的新型组合物
DK09768176T DK2349217T3 (da) 2008-11-14 2009-11-10 Gamma-hydroxysmørsyre-granulat
PE2011001031A PE20120028A1 (es) 2008-11-14 2009-11-10 Nueva composicion a base de acido gamma-hidroxibutirico
CA2743767A CA2743767C (fr) 2008-11-14 2009-11-10 Nouvelle composition a base d'acide gamma-hydroxybutyrique
JP2011543797A JP2012508784A (ja) 2008-11-14 2009-11-10 γ−ヒドロキシ酪酸に基づく新規の組成物
EP09768176.1A EP2349217B1 (fr) 2008-11-14 2009-11-10 Granulé d'acide gamma-hydroxybutyrique
UAA201105987A UA103057C2 (ru) 2008-11-14 2009-11-10 Композиция на основе гамма-гидроксимасляной кислоты
AU2009315441A AU2009315441B2 (en) 2008-11-14 2009-11-10 Novel composition based on gamma-hydroxybutyric acid
TW098138675A TWI446906B (zh) 2008-11-14 2009-11-13 以γ－羥基丁酸為基礎的新穎組成物
ARP090104424A AR074351A1 (es) 2008-11-14 2009-11-16 Composicion a base de acido gamma-hidroxibutirico
TN2011000231A TN2011000231A1 (fr) 2008-11-14 2011-05-11 Nouvelle composition a base d'acide gamma-hydroxybutyrique
IL212847A IL212847A (en) 2008-11-14 2011-05-12 Gamma Acid - Hydroxy Butyric Acid
MA33838A MA32790B1 (fr) 2008-11-14 2011-05-13 Nouvelle composition a base d'acide gamma-hydroxybutyrique
CL2011001114A CL2011001114A1 (es) 2008-11-14 2011-05-13 Granulado que comprende un nucleo solido, y alrededor de el una capa de casco constituida por acido gamma-hidroxibutirico, y un ligante; composicion farmaceutica; procedimiento de preparacion del granulado; y su uso para el tratamiento de catalepsia en pacientes narcolepticos o sindrome de abstinencia del alcoholismo.
ZA2011/03542A ZA201103542B (en) 2008-11-14 2011-05-13 Novel composition based on gamma-hydroxybutric acid
CU20110109A CU20110109A7 (es) 2008-11-14 2011-05-13 Nueva composición a base de ácido gamma-hidroxibutírico
CO11059012A CO6382106A2 (es) 2008-11-14 2011-05-13 Nueva composicion a base de acido gamma-hidroxibutirico
CY20191101121T CY1122209T1 (el) 2008-11-14 2019-10-30 Νεα συνθεση με βαση κοκκιου του γ-υδροξυβουτυρικου οξεος

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0857763A FR2938431B1 (fr) 2008-11-14 2008-11-14 Nouvelle composition a base d'acide gamma-hydroxybutyrique

Publications (2)

Publication Number Publication Date
FR2938431A1 FR2938431A1 (fr) 2010-05-21
FR2938431B1 true FR2938431B1 (fr) 2013-12-20

Family

ID=40674006

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0857763A Expired - Fee Related FR2938431B1 (fr) 2008-11-14 2008-11-14 Nouvelle composition a base d'acide gamma-hydroxybutyrique

Country Status (34)

Country Link
US (1) US8529954B2 (enExample)
EP (1) EP2349217B1 (enExample)
JP (1) JP2012508784A (enExample)
KR (1) KR101563390B1 (enExample)
CN (2) CN104688691A (enExample)
AR (1) AR074351A1 (enExample)
AU (1) AU2009315441B2 (enExample)
BR (1) BRPI0916021B8 (enExample)
CA (1) CA2743767C (enExample)
CL (1) CL2011001114A1 (enExample)
CO (1) CO6382106A2 (enExample)
CU (1) CU20110109A7 (enExample)
CY (1) CY1122209T1 (enExample)
DK (1) DK2349217T3 (enExample)
EA (1) EA023305B1 (enExample)
ES (1) ES2749803T3 (enExample)
FR (1) FR2938431B1 (enExample)
HR (1) HRP20191911T1 (enExample)
HU (1) HUE046321T2 (enExample)
IL (1) IL212847A (enExample)
LT (1) LT2349217T (enExample)
MA (1) MA32790B1 (enExample)
MX (1) MX2011005073A (enExample)
NZ (1) NZ592850A (enExample)
PE (1) PE20120028A1 (enExample)
PL (1) PL2349217T3 (enExample)
PT (1) PT2349217T (enExample)
SI (1) SI2349217T1 (enExample)
SM (1) SMT201900721T1 (enExample)
TN (1) TN2011000231A1 (enExample)
TW (1) TWI446906B (enExample)
UA (1) UA103057C2 (enExample)
WO (1) WO2010055260A1 (enExample)
ZA (1) ZA201103542B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2949061B1 (fr) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3727348A1 (en) * 2017-12-20 2020-10-28 Flamel Ireland Limited Packaged modified release gamma-hydroxybutyrate formulations having improved stability
BR112021006027A2 (pt) * 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
AU2020231916B2 (en) * 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CN115244028A (zh) 2019-12-20 2022-10-25 凯瑞康宁生物工程有限公司 4-缬氨酰氧基丁酸的合成方法
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
AU2021292406B2 (en) * 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
AU2021293941B2 (en) * 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
CN115666527B (zh) 2020-10-05 2025-03-07 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的修饰释放组合物
CN112868909A (zh) * 2021-01-22 2021-06-01 湖北神舟化工有限公司 一种无臭型丁酸钠及其生产方法
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
WO2022218364A1 (en) * 2021-04-16 2022-10-20 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Coated beta hydroxybutyric acid crystal and methods for producing the same
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN117413958A (zh) * 2023-12-04 2024-01-19 湖北中烟工业有限责任公司 一种加热不燃烧烟草制品发烟段物料及其制作工艺和加热不燃烧烟草制品

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
JP3447042B2 (ja) * 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
GB9725219D0 (en) 1997-11-29 1998-01-28 Cleansharp Ltd Tablets
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
JP4374441B2 (ja) * 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
PT1178778E (pt) * 1999-05-17 2006-06-30 D B F Granulos que contem uma substancia vegetal e o seu procedimento de preparacao
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
FR2829933B3 (fr) 2001-09-21 2004-03-12 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu
EP2422773A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
MXPA06009991A (es) 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
US20070092565A1 (en) 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
WO2009072334A1 (ja) * 2007-12-03 2009-06-11 Tomita Pharmaceutical Co., Ltd. 製剤用核粒子
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments

Also Published As

Publication number Publication date
NZ592850A (en) 2012-11-30
IL212847A0 (en) 2011-07-31
BRPI0916021B8 (pt) 2021-05-25
AR074351A1 (es) 2011-01-12
PL2349217T3 (pl) 2020-03-31
DK2349217T3 (da) 2019-11-04
KR101563390B1 (ko) 2015-11-06
MA32790B1 (fr) 2011-11-01
SI2349217T1 (sl) 2020-01-31
AU2009315441B2 (en) 2015-02-26
CY1122209T1 (el) 2020-11-25
CL2011001114A1 (es) 2011-09-02
MX2011005073A (es) 2011-10-12
TWI446906B (zh) 2014-08-01
SMT201900721T1 (it) 2020-01-14
AU2009315441A1 (en) 2010-05-20
EP2349217B1 (fr) 2019-07-31
EA201100758A1 (ru) 2011-12-30
TW201031401A (en) 2010-09-01
CO6382106A2 (es) 2012-02-15
HRP20191911T1 (hr) 2020-01-10
BRPI0916021B1 (pt) 2020-01-14
HUE046321T2 (hu) 2020-02-28
PE20120028A1 (es) 2012-02-25
EP2349217A1 (fr) 2011-08-03
WO2010055260A1 (fr) 2010-05-20
BRPI0916021A2 (pt) 2015-11-10
US8529954B2 (en) 2013-09-10
IL212847A (en) 2015-02-26
ZA201103542B (en) 2012-01-25
UA103057C2 (ru) 2013-09-10
CA2743767C (fr) 2019-06-25
TN2011000231A1 (fr) 2012-12-17
PT2349217T (pt) 2019-11-04
FR2938431A1 (fr) 2010-05-21
CA2743767A1 (fr) 2010-05-20
LT2349217T (lt) 2019-11-11
CN104688691A (zh) 2015-06-10
EA023305B1 (ru) 2016-05-31
ES2749803T3 (es) 2020-03-23
CN102215822A (zh) 2011-10-12
JP2012508784A (ja) 2012-04-12
KR20110099011A (ko) 2011-09-05
CU20110109A7 (es) 2012-01-31
US20110293729A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
FR2938431B1 (fr) Nouvelle composition a base d'acide gamma-hydroxybutyrique
CY1113131T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
EA201070966A1 (ru) Фолаты, композиции и применение указанных композиций
EA201290097A1 (ru) Спиртовые композиции, имеющие пониженный риск возникновения ацетальдегидемии
CY1117228T1 (el) Διεργασια για την παρασκευη συνθεσεων υδροχλωρικης οξυκωδονης που εχουν λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
MA29539B1 (fr) Procedes de production de derives phenoliques 4-biphenylylazetidin -2-one
TW200730490A (en) Photoactive compounds
TN2009000085A1 (fr) Derives de pyrido (2,3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3
IL187586A (en) A method of generating dihydroquinazolines
NO20073678L (no) Nye fremgangsmater for fremstilling av benzofuran
MX2008014898A (es) Composicion para el diagnostico de enfermedades relacionadas con amiloides.
EA200702614A1 (ru) Способы получения 4-(бифенилил)азетидин-2-оналкилфосфиновых кислот
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
EA200701810A1 (ru) Производное изоксазолина и новый способ его получения
NO20081617L (no) Metoder for fremstilling av Glutaminsyrederivater
IL187640A0 (en) Method for preparing clopidogrel and intermediates used therein
EA200800810A1 (ru) Соль глюкуроновой кислоты и соединения пиперазина
WO2010036640A3 (en) Compounds for the treatment of inflammatory disorders
MA29496B1 (fr) Procede de production de 4-biphenylyazetidin-2-ones
GEP20094786B (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
EA200801297A1 (ru) Способ снижения уровня постпрандиальной глюкозы
FR2905562B1 (fr) Nouvelle preparation de phosphodiesterase d'orgine vegetale
SI2016073T1 (sl) Postopek za pripravo ÄŤistega irbesartana
EA200600542A1 (ru) Способ для производства thip

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

ST Notification of lapse

Effective date: 20250705